Demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: An international, two-center cohort study

Nenhuma Miniatura disponível
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
TURKISH LEAGUE AGAINST RHEUMATISM (TLAR)
Autores
RATHORE, U.
AGARWAL, V.
GUPTA, L.
Citação
ARCHIVES OF RHEUMATOLOGY, v.37, n.3, p.424-434, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objectives: To compare clinical, demographic, laboratory data, prognostic and treatment characteristics of patients with antisynthetase syndrome (ASSD) treated in two different centers of India and Brazil. Patients and methods: This international, two-center, retro-prospective cohort study which was conducted at two tertiary rheumatology centers (one in Brazil and one in India) between January 2000 to January 2020 included a total of 115 patients with ASSD (21 males, 94 females; mean age; at disease diagnosis at 40.3; range, 18 to 80 years). Demographic, clinical and laboratory data of the patients were recorded. Clinical involvement was evaluated. Results: Of the patients, 81 were Brazilians and 34 were of Indian origin. The Indian group exhibited a greater delay in diagnosis after the onset of symptoms compared to Brazilian patients (12 vs. 6 months, respectively; p=0.026). Brazilian patients exhibited a significantly higher prevalence of joint and lung involvement, mechanic’s hands, and Raynaud’s phenomenon. Anti-Jo-1 was the most common autoantibodies in both groups. Systemic arterial hypertension, followed by diabetes mellitus were the most prevalent comorbidities. Concerning previously used drugs, the Indian patients had a larger group of patients treated with antimalarials, whereas the Brazilian group used more azathioprine and intravenous immunoglobulin. A higher proportion of Indian patients was treated with one immunosuppressive drug (70.6%), while the Brazilian group were often treated using two immunosuppressive drugs (33%). Comparison between the severity and prognosis showed that Brazilian group had a higher number of relapses, and during follow-up, the global mortality rates were similar in both groups (6.2% for Brazilian vs. 8.8% for Indian). Conclusion: Brazilian and Indian patients with ASSD have comparable epidemiological characteristics such as age at the time of disease diagnosis, and sex distribution, and autoantibodies. Diagnostic delay is seen in Indian patients, and Brazilians exhibit a higher prevalence of joint and lung involvement, mechanic’s hands, Raynaud’s phenomenon with a higher number of relapses, although the mortality rate seems to be similar in both groups.
Palavras-chave
Antisynthetase syndrome, dermatomyositis, myositis, outcomes
URI
https://observatorio.fm.usp.br/handle/OPI/58607
Referências
  1. Shinjo SK, Levy-Neto M., Anti-Jo-1 antisynthetase syndrome, Rev Bras Reumatol, 50, pp. 492-500, (2010)
  2. Cavagna L, Castaneda S, Scire C, Gonzalez-Gay MA, Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria, Ann Rheum Dis, 77, (2018)
  3. Katzap E, Barilla-LaBarca ML, Marder G., Antisynthetase syndrome, Curr Rheumatol Rep, 13, pp. 175-181, (2011)
  4. Hervier B, Benveniste O., Clinical heterogeneity and outcomes of antisynthetase syndrome, Curr Rheumatol Rep, 15, (2013)
  5. Mahler M, Miller FW, Fritzler MJ., Idiopathic inflammatory myopathies and the anti-synthetase syndrome: A comprehensive review, Autoimmun Rev, 13, pp. 367-371, (2014)
  6. Souza FH, Cruellas MG, Levy-Neto M, Shinjo SK., Anti-synthetase syndrome: Anti-PL-7, anti-PL-12 and anti-EJ, Rev Bras Reumatol, 53, pp. 352-357, (2013)
  7. Cojocaru M, Cojocaru IM, Chicos B., New insights into antisynthetase syndrome, Maedica (Bucur), 11, pp. 130-135, (2016)
  8. Rojas-Serrano J, Herrera-Bringas D, Mejia M, Rivero H, Mateos-Toledo H, Figueroa JE., Prognostic factors in a cohort of antisynthetase syndrome (ASS): Serologic profile is associated with mortality in patients with interstitial lung disease (ILD), Clin Rheumatol, 34, pp. 1563-1569, (2015)
  9. Hervier B, Devilliers H, Stanciu R, Meyer A, Uzunhan Y, Masseau A, Et al., Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity, Autoimmun Rev, 12, pp. 210-217, (2012)
  10. Monti S, Montecucco C, Cavagna L., Clinical spectrum of anti-Jo-1-associated disease, Curr Opin Rheumatol, 29, pp. 612-617, (2017)
  11. Opinc AH, Makowska JS., Antisynthetase syndrome-much more than just a myopathy, Semin Arthritis Rheum, 51, pp. 72-83, (2021)
  12. Shi J, Li S, Yang H, Zhang Y, Peng Q, Lu X, Et al., Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies, J Rheumatol, 44, pp. 1051-1057, (2017)
  13. Gupta L, Appani SK, Janardana R, Muhammed H, Lawrence A, Amin S, Et al., Meeting report: MyoIN – Pan-India collaborative network for myositis research, Indian J Rheumatol, 14, pp. 136-142, (2019)
  14. Naveen R, Anuja AK, Rai MK, Agarwal V, Gupta L., Development of the MyoCite biobank: Cost-efficient model of public sector investigator-driven biobank for idiopathic inflammatory myositis, Indian J Rheumatol, 15, pp. 194-199, (2020)
  15. Mehta P, Gupta L., Combined case record forms for collaborative datasets of patients and controls of idiopathic inflammatory myopathies, Indian J Rheumatol, 15, pp. 191-193, (2020)
  16. Behrens Pinto GL, Carboni RCS, de Souza FHC, Shinjo SK., A prospective cross-sectional study of serum IL-17A in antisynthetase syndrome, Clin Rheumatol, 39, pp. 2763-2771, (2020)
  17. Cavagna L, Trallero-Araguas E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E, Et al., Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course, J Clin Med, 8, (2019)
  18. Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, Et al., Defining clinical improvement in adult and juvenile myositis, J Rheumatol, 30, pp. 603-617, (2003)
  19. Harris-Love MO, Shrader JA, Koziol D, Pahlajani N, Jain M, Smith M, Et al., Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis, Rheumatology (Oxford), 48, pp. 134-139, (2009)
  20. Vanhoutte EK, Faber CG, van Nes SI, Jacobs BC, van Doorn PA, van Koningsveld R, Et al., Modifying the Medical Research Council grading system through Rasch analyses, Brain, 135, pp. 1639-1649, (2012)
  21. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Et al., American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation, Am J Respir Crit Care Med, 173, pp. 1390-1413, (2006)
  22. Baccaro ACCD, Behrens Pinto GL, Carboni RCS, Shinjo SK., The clinical manifestations at the onset of antisynthetase syndrome: A chameleon with multiple faces, Reumatismo, 72, pp. 86-92, (2020)
  23. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension, J Hypertens, 31, pp. 1925-1938, (2013)
  24. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Et al., American Association of Clinical Endocrinologists and American College of Endocrinology--clinical practice guidelines for developing a diabetes mellitus comprehensive care plan--2015--executivesummary, Endocr Pract, 21, pp. 413-437, (2015)
  25. Sultan SM, Allen E, Oddis CV, Kiely P, Cooper RG, Lundberg IE, Et al., Reliability and validity of the myositis disease activity assessment tool, Arthritis Rheum, 58, pp. 3593-3599, (2008)
  26. Gupta L, Naveen R, Gaur P, Agarwal V, Aggarwal R., Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis, Semin Arthritis Rheum, 51, pp. 113-120, (2021)
  27. Witt LJ, Curran JJ, Strek ME., The diagnosis and treatment of antisynthetase syndrome, Clin Pulm Med, 23, pp. 218-226, (2016)
  28. Zanframundo G, Marasco E, Carrubba C, Stefano LD, Volpiano L, Tirelli C, Et al., Update on treatment of antisynthetase syndrome: A brief review, Current Treatment Options in Rheumatology, 6, pp. 18-28, (2020)
  29. Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS., Long-term side effects of glucocorticoids, Expert Opin Drug Saf, 15, pp. 457-465, (2016)
  30. Mira-Avendano IC, Parambil JG, Yadav R, Arrossi V, Xu M, Chapman JT, Et al., A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis, Respir Med, 107, pp. 890-896, (2013)
  31. Marco JL, Collins BF., Clinical manifestations and treatment of antisynthetase syndrome, Best Pract Res Clin Rheumatol, 34, (2020)
  32. Ge Y, Peng Q, Zhang S, Zhou H, Lu X, Wang G., Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: A systematic review, Clin Rheumatol, 34, pp. 99-105, (2015)
  33. Chatterjee R, Mehta P, Agarwal V, Gupta L., High burden of infections in Indian patients with Idiopathic Inflammatory Myopathy: Validation of observations from the MyoCite dataset, Rheumatology (Oxford), 60, pp. 4315-4326, (2021)
  34. Mehta P, Agarwal V, Gupta L., High early mortality in idiopathic inflammatory myopathies: Results from the inception cohort at a tertiary care centre in Northern India, Rheumatology (Oxford), 60, pp. 4281-4290, (2021)
  35. Muhammed H, Gupta L, Zanwar AA, Misra DP, Lawrence A, Agarwal V, Et al., Infections are leading cause of in-hospital mortality in Indian patients with inflammatory myopathy, J Clin Rheumatol, 27, pp. 114-119, (2021)
  36. Kumar RR, Jha S, Dhooria A, Naidu GSRSNK, Minz RW, Kumar S, Et al., Anti-Jo-1 syndrome often misdiagnosed as rheumatoid arthritis (for many years): A single-center experience, J Clin Rheumatol, 27, pp. 150-155, (2021)
  37. Brulhart L, Waldburger JM, Gabay C., Rituximab in the treatment of antisynthetase syndrome, Ann Rheum Dis, 65, pp. 974-975, (2006)
  38. Dugar M, Cox S, Limaye V, Blumbergs P, Roberts-Thomson PJ., Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies, Intern Med J, 41, pp. 674-679, (2011)
  39. Doyle TJ, Dhillon N, Madan R, Cabral F, Fletcher EA, Koontz DC, Et al., Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: A multicenter retrospective case review, J Rheumatol, 45, pp. 841-850, (2018)
  40. Araujo PAO, Silva MG, Borba EF, Shinjo SK., High prevalence of metabolic syndrome in antisynthetase syndrome, Clin Exp Rheumatol, 36, pp. 241-247, (2018)
  41. International Diabetes Federation, (2015)
  42. Imbert-Masseau A, Hamidou M, Agard C, Grolleau JY, Cherin P., Antisynthetase syndrome, Joint Bone Spine, 70, pp. 161-168, (2003)
  43. Sultan SM, Ioannou Y, Moss K, Isenberg DA., Outcome in patients with idiopathic inflammatory myositis: Morbidity and mortality, Rheumatology (Oxford), 41, pp. 22-26, (2002)
  44. Triantafyllias K, Cavagna L, Klonowski A, Drott U, Fiehn C, Wendel S, Et al., Possible misclassification of cardiovascular risk by SCORE in antisynthetase syndrome: Results of the pilot multicenter study RI.CAR.D.A, Rheumatology (Oxford), 60, pp. 1300-1312, (2021)

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/17
Artigos e Materiais de Revistas Científicas - ODS/03